Search

Displaying results 1991 - 2000 of 8006 in total
  1. Drug

    Lactitol

    go.drugbank.com/drugs/DB12942
    Approved

    [A190915,A190918] Pizensy, an oral lactitol powder for solution, was approved by the FDA for use in chronic idiopathic constipation in February 2020.[L11803] … Lactitol, also known as 4-β-D-galactopyranosyl-D-glucitol, is a sugar alcohol synthesized from [lactose].

    Categories: Drugs for Constipation, Compounds used in a research, industrial, or household setting
  2. Drug

    Calcium levulinate

    go.drugbank.com/drugs/DB13800
    Approved

    The relatively new calcium levulinate is produced from a direct reaction between L- or levulinic acid levulose and calcium hydroxide [L2765]. … Calcium levulinate can be used alone, or with calcium lactate, calcium chloride, and other compounds, either for pharmaceutical tablets, capsules, or injections preparation [L2765].

  3. Drug

    Belzutifan

    go.drugbank.com/drugs/DB15463
    ApprovedInvestigational

    [L35995] The HIF-2α protein was first identified in the 1990s by researchers at UT Southwestern Medical Center as a key player in the growth of certain cancers. … [L36000] It was later approved for the treatment of locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL) in patients aged 12 years and older.[L49271]

  4. Drug

    Aminohippuric acid

    go.drugbank.com/drugs/DB00345
    ApprovedInvestigationalWithdrawn

    Its sodium salt is used as a diagnostic aid to measure effective renal plasma flow (ERPF) and excretory capacity. [PubChem]

    Categories: Tests for Renal Function and Ureteral Injuries, Compounds used in a research, industrial, or household setting
  5. Drug

    Ticagrelor

    go.drugbank.com/drugs/DB08816
    ApprovedInvestigational

    [A2903] It is marketed by Astra Zeneca as Brilinta in the US[L14201] and Brilique or Possia in the EU,[L14207]. Ticagrelor was granted EMA approval on 3 December 2010. … Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism.

  6. Drug

    TrenibotulinumtoxinE

    go.drugbank.com/drugs/DB19082
    Approved

    [L64095] TrenibotulinumtoxinE is distinguished from the serotype A toxins that dominate this setting by its rapid onset and short duration: effects begin around 8 hours after injection, peak at day 7, … TrenibotulinumtoxinE is a botulinum neurotoxin serotype E, produced in *Clostridium botulinum*, used for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.

  7. Drug

    Liotrix

    go.drugbank.com/drugs/DB01583
    Approved

    It is now known that the thyroid gland secretes approximately ten times more T4 than T3 and that 80% of serum T3 is derived from deiodination of T4 in peripheral tissues. … Administration of levothyroxine alone is sufficient for maintaining serum T4 and T3 levels in most patients and combination hormone replacement therapy generally offers no therapeutic advantage.

  8. Drug

    Helium

    go.drugbank.com/drugs/DB09155
    ApprovedInvestigationalVet approved

    Its clinical benefit in inhalation therapy arises from its advantageous physical properties than ambient air.

  9. Drug

    Lorcaserin

    go.drugbank.com/drugs/DB04871
    ApprovedInvestigationalWithdrawn

    Lorcaserin is marketed as a salt form called Belviq, which is lorcaserin hydrochloride. … Lorcaserin (previously APD-356), a highly selective 5HT2C receptor agonist, is used for the treatment of obesity.

  10. Drug

    Lodoxamide

    go.drugbank.com/drugs/DB06794
    Approved

    Lodoxamide is a mast-cell stabilizer for topical administration into the eye. … Lodoxamide is marketed under the brand name Alomide by Alcon.